Navigation Links
Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Date:10/13/2009

hese efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month-formulations of triptorelin.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About Ipsen

Ipsen is an innovation-driven global specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patien
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
2. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
3. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
4. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
5. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
6. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Japanese Cancer Association and Debiopharm Honour Japanese Research
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. Debiopharm and EPFL Establish an Oncology Chair
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Lyme ... funder of Lyme disease research at universities, today announced ... focused on the identification, treatment and cure for Lyme ... had received the most applications in its history—over 20 ... , “While we were pleased to receive so many ...
(Date:9/30/2014)... 30, 2014 UFP Technologies, a ... packaging has recently introduced a custom insulated shipping ... . The new insulated shipper solves the issue ... process. UFP Technologies’ BioShell is a universal storage ... storage, handling and shipping. The insulated shipper keeps ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... and Technology (NIST) and The Johns Hopkins University ... properties of promising new materials with unprecedented sensitivity ... most useful for nanotechnology and industrial applications. , ... (MACS), is a variation on several other spectrometers ...
... N.C., Feb. 25 Cornerstone Therapeutics Inc. (Nasdaq: ... developing and commercializing prescription medications for respiratory disorders, today ... 8:30 AM ET on Thursday, March 26, 2009, to ... ended December 31, 2008. Management will also provide ...
... VINELAND, ON, Feb. 25 /PRNewswire/ - How does a ... to answer that question with its model for the ... horticulture science cluster in Canada, industry will steer the ... Jim Brandle, C.E.O. Vineland Research and Innovation Centre. "And ...
Cached Biology Technology:Nanotechnologists gain powerful new materials probe 2Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call 2Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call 3Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call 4Vineland Enables Industries' Efforts to Build Agri-Science Research Cluster 2
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
(Date:9/29/2014)... Between 1970 and 2010 populations of mammals, birds, ... 52 percent, says the 2014 Living Planet Report ... biodiversity loss occurs disproportionately in low-income countriesand correlates ... , In addition to the precipitous decline in ... warning signs about the overall health of the ...
(Date:9/29/2014)... In order to support the world,s needs ... polymers and more, new and more efficient catalytic ... of researchers, including several from Wayne State University, ... a new grant from the National Science Foundation. ... Design of Multicomponent Materials for Electrocatalytic Cascade Reactions," ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Half of global wildlife lost, says new WWF report 2Wayne State research aims to develop new, more efficient catalytic materials 2
... Investigators have discovered that some type of protective system ... immune system is deficient. This discovery indicates a hidden ... diseases of the immune system such as AIDS. The ... and Baltimore, and is reported in the early online ...
... Medical Center have uncovered part of the genetic mechanism that ... , A team led by SFVAMC vascular surgeon Rajabrata Sarkar, ... is essential for the growth of new arteries when the ... identified and described, for the first time, the specific DNA ...
... in Brazil 40 years ago, Marc A. Meyers marveled at ... on the forest floor. Now a materials scientist and professor ... Engineering, Meyers said makers of airplanes and automobiles may benefit ... conducted in his lab. , "Our computer modeling done shows ...
Cached Biology News:Infant transplant patients resist infections that kill adult AIDS patients 2Infant transplant patients resist infections that kill adult AIDS patients 3Genetic key to growth of new arteries is identified 2Genetic key to growth of new arteries is identified 3Engineers discover why toucan beaks are models of lightweight strength 2
... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
... the denaturation and hybridization steps in slide-based ... clinical and research personnel. The low cost ... types, is easy to use, and reduces ... ensuring overall precision and accuracy in all ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
Biology Products: